ArticleiScience2026
Longitudinal pre-diagnostic blood samples predict osteoporosis risk.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cross-sectional biomarker discovery studies for degenerative diseases are limited by selection bias, post-diagnostic confounding, and high biological variability. Repeated pre-diagnostic sampling can address these limitations. We analyzed 538 plasma metabolomic profiles (1-6 samples per participant, yearly intervals) from 99 pre-diagnostic osteoporosis cases and 99 matched controls in the Danish Blood Donor Study. We compared performance of cross-sectional and longitudinal modeling using least absolute shrinkage and selection operator (LASSO) logistic regression and random forest. Longitudinal LASSO modeling of metabolite trajectories achieved area under the curve (AUC) values between 0.67 and 0.76, outperforming cross-sectional models with AUC values of 0.57-0.63. Batch- and participant-independent validation of the best model demonstrated stable methodology (AUC: 0.70). The longitudinal data revealed that hippuric acid decreased over time in cases while increasing in controls. We conclude that longitudinal sampling costs more per participant, but the substantial information gain makes it a viable strategy when patient recruitment, not sampling capacity, is the bottleneck.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.